Seroquel: Behavioral Effects in Conventional and Novel Tests for Atypical Antipsychotic Drug

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1993 Jan 1

PMID 7871034

Citations 20

Authors

B M Migler

E J Warawa

J B Malick

Affiliations

Soon will be listed here.

Abstract

Seroquel was compared to clozapine and several other antipsychotic agents in tests predictive of antipsychotic activity or extrapyramidal symptoms. In the conditioned avoidance test in squirrel monkeys as well as several paradigms using apomorphine or amphetamine-induced behavioral alterations, seroquel displayed the profile of a drug with potential antipsychotic activity. In these paradigms the potency of seroquel was somewhat less than clozapine in rodent tests, while the reverse was true in higher species, i.e. monkeys, cats. In tests designed to evaluate the propensity to induce EPS or tardive dyskinesia, for example, the production of dyskinetic reactions in haloperidol-sensitized cebus monkeys, seroquel displayed a profile similar to clozapine and disparate from typical antipsychotic drugs. In drug-naive cebus monkeys seroquel sensitized significantly fewer monkeys than haloperidol and the dyskinetic reactions were of significantly less intensity. It is anticipated that this novel antipsychotic agent will have a significantly reduced propensity to produce extrapyramidal symptoms and tardive dyskinesia than typical antipsychotics.

Citing Articles

Antipsychotic quetiapine alters the mouse fecal resistome by impacting antibiotic efflux, cell membrane, and cell wall synthesis genes.

Kyono Y, Magboo J, Daley E, Flowers S Microbiol Spectr. 2023; 12(1):e0380423.

PMID: 38099619 PMC: 10782992. DOI: 10.1128/spectrum.03804-23.

Efficient Construction of Symmetrical Diaryl Sulfides via a Supported Pd Nanocatalyst-Catalyzed C-S Coupling Reaction.

Jin H, Liu P, Teng Q, Wang Y, Meng Q, Qian C Int J Mol Sci. 2022; 23(23).

PMID: 36499687 PMC: 9738011. DOI: 10.3390/ijms232315360.

Influencing Factors of Hospital-Acquired Pneumonia Infection in the Middle-Aged and Elderly Patients With Schizophrenia.

Yang M, Li Q, Wang C, Li L, Xu M, Yan F Front Psychiatry. 2021; 12:746791.

PMID: 34721113 PMC: 8554066. DOI: 10.3389/fpsyt.2021.746791.

Quetiapine : A Review of its Use in Schizophrenia.

Gunasekara N, Spencer C CNS Drugs. 2016; 9(4):325-40.

PMID: 27521016 DOI: 10.2165/00023210-199809040-00007.

Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.

Ota A, Nakashima A, Kaneko Y, Mori K, Nagasaki H, Takayanagi T J Neural Transm (Vienna). 2012; 119(11):1327-42.

PMID: 22392058 DOI: 10.1007/s00702-012-0782-2.

References

Tarsy D . Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol. 1983; 6 Suppl 1:S9-26. View

Barany S, Gunne L . Pharmacological modification of experimental tardive dyskinesia. Acta Pharmacol Toxicol (Copenh). 1979; 45(2):107-11. DOI: 10.1111/j.1600-0773.1979.tb02369.x. View

Kane J, HONIGFELD G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789-96. DOI: 10.1001/archpsyc.1988.01800330013001. View

Morelli M, Di Chiara G . Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol. 1985; 117(2):179-85. DOI: 10.1016/0014-2999(85)90602-8. View

THER L, Schramm H . [Apomorphine synergism (inducedgnawing in mice) as a test for the differentiation of psychotropic substances]. Arch Int Pharmacodyn Ther. 1962; 138:302-10. View

Claghorn J, HONIGFELD G, Abuzzahab Sr F, Wang R, Steinbook R, Tuason V . The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 1987; 7(6):377-84. View

Barany S, Haggstrom J, Gunne L . Application of a primate model for tardive dyskinesia. Acta Pharmacol Toxicol (Copenh). 1983; 52(2):86-9. View

Casey D . Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl). 1989; 99 Suppl:S47-53. DOI: 10.1007/BF00442559. View

Woggon B, Linden M, Beckmann H, Krebs E, Kufferle B, Muller-Oerlinghausen B . The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol. Psychopharmacol Bull. 1986; 22(1):47-51. View

10.

Karson C, Freed W, Kleinman J, BIGELOW L, Wyatt R . Neuroleptics decrease blinking in schizophrenic subjects. Biol Psychiatry. 1981; 16(7):679-82. View

11.

Griffith R, SAAMELI K . Letter: Clozapine and agranulocytosis. Lancet. 1975; 2(7936):657. DOI: 10.1016/s0140-6736(75)90135-x. View

12.

Reynolds G, Czudek C . Status of the dopaminergic system in post-mortem brain in schizophrenia. Psychopharmacol Bull. 1988; 24(3):345-7. View

13.

Shopsin B, Klein H, Aaronsom M, Collora M . Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry. 1979; 36(6):657-64. DOI: 10.1001/archpsyc.1979.01780060047005. View

14.

Stevens J . Eye blink and schizophrenia: psychosis or tardive dyskinesia?. Am J Psychiatry. 1978; 135(2):223-6. DOI: 10.1176/ajp.135.2.223. View

15.

Lieberman J, Johns C, Kane J, Rai K, PISCIOTTA A, Saltz B . Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry. 1988; 49(7):271-7. View

16.

Anger B, Reichert S, Heimpel H . Clozapine-induced agranulocytosis. Blut. 1987; 54(1):63-4. DOI: 10.1007/BF00326033. View

17.

Protais P, Costentin J, Schwartz J . Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl). 1976; 50(1):1-6. DOI: 10.1007/BF00634146. View

18.

BIGELOW L, Nasrallah H, Carman J, Gillin J, Wyatt R . Baclofen treatment in chronic schizophrenia: a clinical trial. Am J Psychiatry. 1977; 134(3):318-20. DOI: 10.1176/ajp.134.3.318. View